Floatz logo

Therapeutic Asset Ratings

18,140 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Fludarabine
Acquired Polycythemia Vera
Thomas Jefferson UniversityP2B (63)
Fludarabine
Precancerous Condition
Institut Paoli-CalmettesP2B (63)
Fluorouracilum
Melanoma
Neonc Technologies, Inc.P2B (63)
Fulvestrant
Invasive Breast Carcinoma
Massachusetts General HospitalP2B (63)
Golidocitinib
Non-Small Cell Lung Carcinoma
Peking University Cancer Hospital & InstituteP2B (63)
Idarubicin
Acute Undifferentiated Leukemia
Fred Hutchinson Cancer CenterP2B (63)
Irinotecan
Melanoma
PfizerP2B (63)
Irinotecan
Papillary Renal Cell Carcinoma
National Cancer Institute (NCI)P2B (63)
Irinotecan
Mycosis Fungoides
Virogen Biotechnology Inc.P2B (63)
Lenalidomide
Cancer
CStone PharmaceuticalsP2B (63)
Lenalidomide
Post-Transplant Lymphoproliferative Disease
Northwestern UniversityP2B (63)
Lenalidomide
Burkitt Lymphoma
National Cancer Institute (NCI)P2B (63)
Letrozole
Progesterone-Receptor Positive Breast Cancer
Ruth O'ReganP2B (63)
Melphalan
HIV Infectious Disease
AIDS Malignancy ConsortiumP2B (63)
Melphalan
B-Cell Chronic Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research InstituteP2B (63)
Methotrexate
Follicular Lymphoma
University of Michigan Rogel Cancer CenterP2B (63)
Methotrexate
Juvenile Myelomonocytic Leukemia
Children's Oncology GroupP2B (63)
Methotrexate
Precancerous Condition
City of Hope Medical CenterP2B (63)
Methotrexate
Sickle Cell Disease
City of Hope Medical CenterP2B (63)
Nogitecan
Small Cell Carcinoma
National Cancer Institute (NCI)P2B (63)
Nogitecan
Brain Neoplasm
Jeffrey N. BruceP2B (63)
Oxaliplatin
Soft Tissue Sarcoma
OHSU Knight Cancer InstituteP2B (63)
Palbociclib
Colon Carcinoma
Lebanese UniversityP2B (63)
Pirtobrutinib
Marginal Zone Lymphoma
University of UtahP2B (63)
Ponatinib
Chronic Myeloid Leukemia
Otsuka Beijing Research InstituteP2B (63)
Showing 2951 to 2975 of 18,140 assets
PreviousPage 119 of 726Next